[1] Kratzer TB, Mazzitelli N, Star J, et al.Prostate cancer statistics, 2025[J]. CA Cancer J Clin, 2025,75(6):485-497. [2] 李星, 曾晓勇. 中国前列腺癌流行病学研究进展[J]. 肿瘤防治研究, 2021, 48(1):98-102. [3] Mottet N, Bergh RCNVD, Briers E, et al.EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent[J]. Eur Urol, 2021,79(2):243-262. [4] Turkbey B, Rosenkrantz AB, Haider MA, etal. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2[J]. Eur Urol, 2019, 76(3):340-351. [5] Epstein JI, Egevad L, Amin MB, et al.The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System[J]. Am J Surg Pathol, 2016,40(2):244-252. [6] Turkbey B,Purysko AS.PI-RADS: Where Next?[J]. Radiology, 2023, 307(5): e223128. [7] 沈蕾, 宋伟, 江帆, 等. MRI动态增强联合ADC在前列腺癌诊断及Gleason分级中的应用[J]. 影像科学与光化学, 2025, 43(5): 124-130+138. [8] 李珍, 邹磊, 弥长虹, 等.前列腺癌磁共振动态增强定量研究[J]. 中国CT和MRI杂志, 2021, 19(7): 126-127+137. [9] Tofts PS, Brix G, Buckley DL, et al.Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols[J]. J Magn Reson Imaging, 1999,10(3):223-232. [10] Spratt DE, Srinivas S, Adra N, et al.Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology[J]. J Natl Compr Canc Netw, 2025, 23(11):469-493. [11] Sandhu JS, Bixler BR, Dahm P, et al.Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023[J]. J Urol, 2024,211(1):11-19. [12] 罗拥志, 王习. 动态对比增强磁共振成像联合扩散加权成像对前列腺中央腺体癌的诊断价值[J]. 磁共振成像, 2021, 12(9): 61-64. [13] 莫庆, 王秀玲, 汪轩. 分析3.0 T动态增强核磁共振成像在前列腺癌与前列腺增生鉴别中的应用价值[J]. 现代医学与健康研究电子杂志, 2022, 6(20): 104-107. [14] 赵斐, 刘荣成, 孙岚. DCE-MRI联合DWI定量分析对前列腺癌的诊断效能及相关参数分析[J]. 临床医学, 2023, 43(10): 96-98. [15] Lou X.Analysis of the Diagnostic Efficacy and Clinical Utility of Multiparametric MRI in Prostate Cancer Diagnosis[J]. Cancer Manag Res, 2025, 17: 1803-1812. [16] Zhu G, Luo J, Ouyang Z, et al.The Assessment of Prostate Cancer Aggressiveness Using a Combination of Quantitative Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging[J]. Cancer Manag Res, 2021, 13: 5287-5295. [17] Stefanou D, Batistatou A, Kamina S, et al.Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer[J]. In Vivo, 2004,18(2):155-160. [18] Carmeliet P, Jain RK.Angiogenesis in cancer and other diseases[J]. Nature, 2000,407(6801):249-257. [19] Benjaminsen IC, Brurberg KG, Ruud EM, et al.Assessment of extravascular extracellular space fraction in human melanoma xenografts by DCE-MRI and kinetic modeling[J]. Magn Reson Imaging, 2008, 26(2): 160-170. [20] Meyer HJ, Wienke A, Surov A. Can dynamic contrast enhanced MRI predict gleason score in prostate cancer? a systematic review and meta analysis[J]. Urol Oncol, 2021,39(11):784.e17-784.e25. |